IntegraGen Reports Loss for First Half of 2016

IntegraGen has announced its revenues for the first half of 2016.

The net result over the first six months of 2016 was a loss of €1,028K compared to a loss of €872K in H1 2015.

Bernard Courtieu, Chief Executive Officer of IntegraGen stated:”These solid financial and operational results confirm our strategy focused on genomics and the development of molecular diagnostic tools. Our Genomic Services business has grown by 10% compared to the same time period in 2015 demonstrating our ability to maintain organic growth while also attracting new prestigious partners for sequencing activities such as the Greater Paris University hospital (AP-HP), a partnership that will provide opportunity for further growth over the next few years. Development efforts for our miR-31-3p biomarker have also reached a very significant milestone with the presentation of the results from the analysis of new clinical trial data at the two largest cancer meetings held in the U.S. and Europe. The very positive results we presented will support IntegraGen’s effort to launch a miR-31-3p diagnostic test in both Europe and in the United States”.